These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1586 related articles for article (PubMed ID: 33657295)

  • 61. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
    Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
    Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
    Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
    Lancet; 2023 Mar; 401(10379):821-832. PubMed ID: 36774933
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
    Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
    Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
    Choueiri TK; Albiges L; Barthélémy P; Iacovelli R; Emambux S; Molina-Cerrillo J; Garmezy B; Barata P; Basu A; Bourlon MT; Moon H; Ratta R; McKay RR; Chehrazi-Raffle A; Hammers H; Heng DYC; Braendle E; Beckermann KE; McGregor BA; Motzer RJ
    Lancet; 2024 Oct; 404(10460):1309-1320. PubMed ID: 39284329
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
    Apolo AB; Nadal R; Girardi DM; Niglio SA; Ley L; Cordes LM; Steinberg SM; Sierra Ortiz O; Cadena J; Diaz C; Mallek M; Davarpanah NN; Costello R; Trepel JB; Lee MJ; Merino MJ; Bagheri MH; Monk P; Figg WD; Gulley JL; Agarwal PK; Valera V; Chalfin HJ; Jones J; Streicher H; Wright JJ; Ning YM; Parnes HL; Dahut WL; Bottaro DP; Lara PN; Saraiya B; Pal SK; Stein MN; Mortazavi A
    J Clin Oncol; 2020 Nov; 38(31):3672-3684. PubMed ID: 32915679
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
    Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
    Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
    Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
    ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
    Ebrahimi H; Dizman N; Meza L; Malhotra J; Li X; Dorff T; Frankel P; Llamas-Quitiquit M; Hsu J; Zengin ZB; Alcantara M; Castro D; Mercier B; Chawla N; Chehrazi-Raffle A; Barragan-Carrillo R; Jaime-Casas S; Govindarajan A; Gillece J; Trent J; Lee PP; Parks TP; Takahashi M; Hayashi A; Kortylewski M; Caporaso JG; Lee K; Tripathi A; Pal SK
    Nat Med; 2024 Sep; 30(9):2576-2585. PubMed ID: 38942995
    [TBL] [Abstract][Full Text] [Related]  

  • 72. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
    Wan X; Zhang Y; Tan C; Zeng X; Peng L
    JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
    Cella D; Choueiri TK; Hamilton M; Blum SI; Ivanescu C; Karu K; Ejzykowicz F; Motzer RJ
    Oncologist; 2024 Jun; 29(6):511-518. PubMed ID: 38280218
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
    Mantia CM; Jegede OA; Plimack ER; Powles T; Motzer RJ; Tannir NM; Lee CH; Tomita Y; Voss MH; Choueiri TK; Rini BI; Hammers HJ; Escudier B; Albigès L; Rosenblatt L; Atkins MB; Regan MM; McDermott DF
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060019
    [TBL] [Abstract][Full Text] [Related]  

  • 76. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
    Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
    N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
    Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
    Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.